Bluesky Facebook Reddit Email

Tumor-suppressing protein may be novel target in PAH therapy

05.19.19 | American Thoracic Society

SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.


ATS 2019, Dallas, TX -- In addition to suppressing tumors, the protein tuberous sclerosis complex 2 (TSC2) may play a role in preventing or treating pulmonary arterial hypertension (PAH), according to research presented at ATS 2019. Researchers found that a deficiency of this protein produced dysfunctional molecules unable to support cell structure and function, resulted in thickening of pulmonary blood vessels and led to PAH.

###

Session: A97 Station to Station: Unraveling the Molecular Pathogenesis of PAH
Abstract Presentation Time: Sunday, May 19, 2:45 p.m. CT
Location: Room C147, 148 and154 (Level 1), Kay Bailey Hutchison Convention Center Dallas

VIEW ABSTRACT

CONTACT FOR MEDIA

Yuanjun Shen, PhD
sheny@pitt.edu

Keywords

Contact Information

How to Cite This Article

APA:
American Thoracic Society. (2019, May 19). Tumor-suppressing protein may be novel target in PAH therapy. Brightsurf News. https://www.brightsurf.com/news/8XGW04Y1/tumor-suppressing-protein-may-be-novel-target-in-pah-therapy.html
MLA:
"Tumor-suppressing protein may be novel target in PAH therapy." Brightsurf News, May. 19 2019, https://www.brightsurf.com/news/8XGW04Y1/tumor-suppressing-protein-may-be-novel-target-in-pah-therapy.html.